Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of January 2024 for Addex Therapeutics Ltd., a foreign private issuer headquartered in Geneva, Switzerland. The filing primarily addresses significant changes to the Company's capital raising mechanisms, specifically the termination of a prior sales agreement and the execution of a new at-the-market (ATM) offering program.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. The only specific financial data disclosed relates to the prior sales agreement:
- Historical Proceeds: Under the terminated Cantor Sales Agreement, the Company sold 1,200 ADSs (representing 7,200 Ordinary Shares) through January 26, 2024.
- Average Price: $10.12 per ADS.
- Gross Proceeds: Approximately $12,000.
- Recent Activity: No sales were made under the Cantor agreement since December 15, 2021.
Material Changes
The Company executed two material transactions regarding its equity offering capabilities:
- Termination of Cantor Agreement: On January 29, 2024, Addex terminated its Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co., effective immediately. This agreement, originally dated June 29, 2021, had not been utilized for sales since December 2021.
- New ATM Agreement: On January 30, 2024, the Company entered into a new At The Market Offering Agreement with H.C. Wainwright & Co., LLC. This agreement authorizes the sale of ADSs with an aggregate offering price of up to $2.15 million.
Outlook, Management Commentary, and Risks
Management Commentary: The Company retains sole discretion over the timing and amount of any sales under the new ATM Agreement with H.C. Wainwright. The Company is not obligated to make any sales.
Terms of New Agreement:
- Commission: H.C. Wainwright will receive a commission of 3.0% of gross sales proceeds.
- Method: Sales may be made via the Nasdaq Capital Market or other existing trading markets deemed "at-the-market" offerings.
- Termination: Either party may suspend or terminate the offering upon notice.
Risks and Contingencies: The filing notes that the report does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful prior to registration. The Company's ability to raise capital is subject to market conditions and the Company's discretion.
Investor Verification Checklist
- Verify the current share price and trading volume of Addex ADSs on the Nasdaq Capital Market to assess the feasibility of the new $2.15 million ATM program.
- Review the full text of the new ATM Agreement (Exhibit 1.1) for specific conditions, price floors, or volume limits not detailed in this summary.
- Confirm the Company's current cash position and burn rate from the most recent Form 20-F or quarterly report to understand the urgency of capital raising.
- Monitor for future filings indicating the first sale of shares under the new H.C. Wainwright agreement.